TABLE 1.
Demographics and clinical characteristics
| Non‐NKTCL | NKTCL | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | Total (n = 60) | First line (n = 7) | Refractory (n = 33) | Relapsed (n = 20) | p‐value | Total (n = 15) | First line (n = 7) | Refractory (n = 6) | Relapsed (n = 2) | p‐value |
| Age at ICE treatment, years | ||||||||||
| Median (range) | 51.5 (21–71) | 55 (26–62) | 52 (21–71) | 48 (21–70) | .826 | 49 (25–68) | 51 (36–68) | 45 (25–53) | 43 (37–49) | .367 |
| ≤ 60 | 47 (78.3) | 5 (71.4) | 26 (78.8) | 16 (80.0) | .819 | 13 (86.7) | 5 (71.4) | 6 (100) | 2 (100) | .600 |
| > 60 | 13 (21.7) | 2 (28.6) | 7 (21.2) | 4 (20.0) | 2 (13.3) | 2 (28.6) | 0 (0) | 0 (0) | ||
| Gender | .043 | .723 | ||||||||
| Male | 46 (76.7) | 3 (42.9) | 25 (75.8) | 18 (90.0) | 12 (80.0) | 6 (85.7) | 4 (66.7) | 2 (100) | ||
| Female | 14 (23.3) | 4 (57.1) | 8 (24.2) | 2 (10.0) | 3 (20.0) | 1 (14.3) | 2 (33.3) | 0 (0) | ||
| Race | .994 | 1.000 | ||||||||
| Chinese | 45 (75.0) | 6 (85.7) | 25 (75.8) | 14 (70.0) | 13 (86.7) | 5 (71.4) | 6 (100) | 2 (100) | ||
| Indian | 5 (8.3) | 0 (0) | 3 (9.1) | 2 (10.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| Malay | 4 (6.7) | 0 (0) | 2 (6.1) | 2 (10.0) | 1 (6.7) | 1 (14.3) | 0 (0) | 0 (0) | ||
| Others | 6 (10.0) | 1 (14.3) | 3 (9.1) | 2 (10.0) | 1 (6.7) | 1 (14.3) | 0 (0) | 0 (0) | ||
| Histology | .155 | |||||||||
| PTCL‐NOS | 26 (43.3) | 4 (57.1) | 17 (51.5) | 5 (25.0) | ||||||
| ALCL | 13 (21.7) | 1 (14.3) | 6 (18.2) | 6 (30.0) | NA | |||||
| AITL | 17 (28.3) | 1 (14.3) | 7 (21.2) | 9 (45.0) | ||||||
| EATL, HSTL | 4 (6.7) | 1 (14.3) | 3 (9.1) | 0 (0) | ||||||
| Stage at diagnosis | <.001 | .089 | ||||||||
| 1 | 2 (3.3) | 1 (14.3) | 0 (0) | 1 (5.0) | 1 (6.7) | 0 (0) | 0 (0) | 1 (50.0) | ||
| 2 | 8 (13.3) | 4 (57.1) | 0 (0) | 4 (20.0) | 3 (20.0) | 0 (0) | 3 (50.0) | 0 (0) | ||
| 3 | 15 (25.0) | 0 (0) | 8 (24.2) | 7 (35.0) | 1 (6.7) | 1 (14.3) | 0 (0) | 0 (0) | ||
| 4 | 35 (58.3) | 2 (28.6) | 25 (75.8) | 8 (40.0) | 10 (66.7) | 6 (85.7) | 3 (50.0) | 1 (50.0) | ||
| B symptoms | .022 | .790 | ||||||||
| Yes | 10 (16.7) | 3 (42.9) | 2 (6.1) | 5 (25.0) | 6 (40.0) | 2 (28.6) | 3 (50.0) | 1 (50.0) | ||
| No | 47 (78.3) | 4 (57.1) | 30 (90.9) | 13 (65.0) | 9 (60.0) | 5 (71.4) | 3 (50.0) | 1 (50.0) | ||
| Unknown | 3 (5.0) | 0 (0) | 1 (3.0) | 2 (10.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| LDH | .214 | .400 | ||||||||
| Elevated | 25 (41.7) | 2 (28.6) | 15 (45.5) | 8 (40.0) | 2 (13.3) | 1 (14.3) | 0 (0) | 1 (50.0) | ||
| Normal | 12 (20.0) | 3 (42.9) | 4 (12.1) | 5 (25.0) | 3 (20.0) | 3 (42.9) | 0 (0) | 0 (0) | ||
| Unknown | 23 (38.3) | 2 (28.6) | 14 (42.4) | 7 (35.0) | 10 (66.7) | 3 (42.9) | 6 (100) | 1 (50.0) | ||
| Extranodal involvement | .820 | .133 | ||||||||
| Yes | 44 (73.3) | 6 (85.7) | 25 (75.8) | 13 (65.0) | 14 (93.3) | 7 (100) | 6 (100) | 1 (50.0) | ||
| No | 13 (21.7) | 1 (14.3) | 7 (21.2) | 5 (25.0) | 1 (6.7) | 0 (0) | 0 (0) | 1 (50.0) | ||
| Unknown | 3 (5.0) | 0 (0) | 1 (3.0) | 2 (10.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| ECOG performance status | .583 | 1.000 | ||||||||
| 0 | 38 (63.3) | 6 (85.7) | 18 (54.5) | 14 (70.0) | 6 (40.0) | 3 (42.9) | 2 (33.3) | 1 (50.0) | ||
| 1 | 11 (18.3) | 1 (14.3) | 8 (24.2) | 2 (10.0) | 1 (6.7) | 1 (14.3) | 0 (0) | 0 (0) | ||
| 2 | 2 (3.3) | 0 (0) | 2 (6.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| Unknown | 9 (15.0) | 0 (0) | 5 (15.2) | 4 (20.0) | 8 (53.3) | 3 (42.9) | 4 (66.7) | 1 (50.0) | ||
| IPI | .553 | NA | ||||||||
| Low | 7 (11.7) | 2 (28.6) | 2 (6.1) | 3 (15.0) | 1 (6.7) | 1 (14.3) | 0 (0) | 0 (0) | ||
| Low‐intermediate | 3 (5.0) | 1 (14.3) | 1 (3.0) | 1 (5.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| High‐intermediate | 10 (16.7) | 1 (14.3) | 7 (21.2) | 2 (10.0) | 1 (6.7) | 1 (14.3) | 0 (0) | 0 (0) | ||
| High | 3 (5.0) | 1 (14.3) | 2 (6.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| Unknown | 37 (61.7) | 2 (28.6) | 21 (63.6) | 14 (70.0) | 13 (86.7) | 5 (71.4) | 6 (100) | 2 (100) | ||
Note: Data presented as No. (%) unless otherwise indicated.
Abbreviation: IPI, International Prognostic Index.